Journal of Thrombosis and Thrombolysis

, Volume 31, Issue 2, pp 133–138 | Cite as

Venous thromboembolism in the US: does race matter?

  • Steven B. DeitelzweigEmail author
  • Jay Lin
  • Barbara H. Johnson
  • Kathy L. Schulman


Studies investigating racial differences in the prevalence of venous thromboembolism (VTE) have generally been conducted on a limited scale. This analysis measured VTE prevalence across racial groups in a population of US Medicaid enrollees from 2002 to 2005. Records for patients aged ≥18 years with VTE between January 1, 2002 and December 31, 2005 were retrieved from the MarketScan® Multi-State Medicaid Database from Thomson Reuters. Patients were classified as having VTE in each calendar year by the presence of a VTE diagnosis on an inpatient claim or ≥1 outpatient claim with VTE diagnosis plus evidence of anticoagulant use. Patients dually eligible for Medicaid and Medicare were excluded. Logistic regression was used to calculate the odds of VTE. An average of 4.5 million Medicaid enrollees were study eligible in each calendar year, 72.2% of which had deep-vein thrombosis, 22.5% pulmonary embolism, and 5.3% had both. Patients were mainly Caucasian (46.8%), African-American (26.0%), and Hispanic (14.1%). VTE prevalence per 100,000 enrollees was highest in African-American males (584 in 2002–784 in 2005), followed by Caucasian males (457–643), Caucasian females (335–446), and African-American females (348–444). Hispanic males (94–149) and females (93–154) had lower prevalence of VTE. African-Americans had a significantly higher probability of having a VTE event than Caucasians (adjusted odds ratio 1.04, 95% confidence interval 1.00–1.07, P = 0.036). VTE prevalence increased over the study period and was highest in African-American males. More coordinated efforts are required to improve VTE awareness and prevention across all racial and ethnic groups.


Venous thromboembolism Race/ethnicity Prevalence Gender 



The authors would like to thank Helen Varker for her programming and analysis, and Bevan Kirley for her editorial contribution to this study. This study was funded by Sanofi-Aventis, US Inc. The authors received editorial and writing support in the preparation of this manuscript, funded by Sanofi-Aventis US, Inc. The lead author, however, was fully responsible for all content and editorial decisions, and received no financial support or other form of compensation related to the development of the paper.


  1. 1.
    Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl 6):381S–453SCrossRefPubMedGoogle Scholar
  2. 2.
    Silverstein MD, Heit JA, Mohr DN et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585–593CrossRefPubMedGoogle Scholar
  3. 3.
    Heit JA, Silverstein MD, Mohr DN et al (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86:452–463PubMedGoogle Scholar
  4. 4.
    Heit JA, Petterson TM, Farmer SA et al. (2006) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 35-year population-based study. Blood 108 (abstract 1488)Google Scholar
  5. 5.
    Dowling NF, Austin H, Dilley A et al (2003) The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE study. J Thromb Haemost 1:80–87CrossRefPubMedGoogle Scholar
  6. 6.
    Stein PD, Kayali F, Olson RE, Milford CE (2004) Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 116:435–442CrossRefPubMedGoogle Scholar
  7. 7.
    Stein PD, Kayali F, Olson RE, Milford CE (2004) Pulmonary thromboembolism in American Indians and Alaskan Natives. Arch Intern Med 164:1804–1806CrossRefPubMedGoogle Scholar
  8. 8.
    White RH, Zhou H, Romano PS (1998) Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 128:737–740PubMedGoogle Scholar
  9. 9.
    White RH, Zhou H, Murin S, Harvey D (2005) Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 93:298–305PubMedGoogle Scholar
  10. 10.
    White RH, Dager WE, Zhou H, Murin S (2006) Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost 96:267–273PubMedGoogle Scholar
  11. 11.
    Christiansen-Lindquist L, Tao G, Hoover K et al (2009) Chlamydia screening of young sexually active, Medicaid-insured women by race and ethnicity, 2002–2005. Sex Transm Dis 36:642–646CrossRefPubMedGoogle Scholar
  12. 12.
    Mark TL, Axelsen KJ, Mucha L, Sadkova Y (2007) Racial differences in switching, augmentation, and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. Am J Manag Care 13(Suppl 3):S72–S79PubMedGoogle Scholar
  13. 13.
    Rousculp MD, Long SR, Wang S et al (2007) Economic burden of osteoporosis-related fractures in Medicaid. Value Health 10:144–152CrossRefPubMedGoogle Scholar
  14. 14.
    US Census Bureau (2000) Projections of the resident population by race, Hispanic origin, and nativity: middle series, 2050–2070. Population projections program, population division, US Census Bureau, Washington, DC. Accessed 16 April 2010
  15. 15.
    McKinnon J (2002) The black population in the United States: March 2002. US Census Bureau, current population reports, series P20-541. Washington, DC. Accessed 16 April 2010
  16. 16.
    Ramirez RR, de la Cruz GP (2002) The Hispanic population in the United States: March 2002. US Census Bureau, current population reports, series P20-545. Washington, DC. Accessed 16 April 2010

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Steven B. Deitelzweig
    • 1
    Email author
  • Jay Lin
    • 2
  • Barbara H. Johnson
    • 3
  • Kathy L. Schulman
    • 3
  1. 1.Ochsner Clinic FoundationNew OrleansUSA
  2. 2.Sanofi-AventisBridgewaterUSA
  3. 3.Healthcare, Thomson ReutersCambridgeUSA

Personalised recommendations